4.6 Review

Mitochondrial Permeability Transition: New Findings and Persisting Uncertainties

Journal

TRENDS IN CELL BIOLOGY
Volume 26, Issue 9, Pages 655-667

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcb.2016.04.006

Keywords

-

Categories

Funding

  1. Fondation pour la Recherche Medicale (FRM)
  2. Ligue Contre le Cancer (Equipe Labellisee)
  3. Agence National de la Recherche (ANR)-Projets Blancs
  4. ANR
  5. ERA-Net for Research on Rare Diseases
  6. Association Pour la Recherche sur le Cancer (ARC)
  7. Canceropole Ile-de-France
  8. Institut National du Cancer (INCa)
  9. Fondation Bettencourt-Schueller
  10. Fondation de France
  11. FRM
  12. European Commission (ArtForce)
  13. European Research Council (ERC)
  14. LabEx Immuno-Oncology
  15. SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
  16. SIRIC Cancer Research and Personalized Medicine (CARPEM)
  17. Paris Alliance of Cancer Research Institutes (PACRI)
  18. Fondation pour la Recherche Medicale (FRM)
  19. Ligue Contre le Cancer (Equipe Labellisee)
  20. Agence National de la Recherche (ANR)-Projets Blancs
  21. ANR
  22. ERA-Net for Research on Rare Diseases
  23. Association Pour la Recherche sur le Cancer (ARC)
  24. Canceropole Ile-de-France
  25. Institut National du Cancer (INCa)
  26. Fondation Bettencourt-Schueller
  27. Fondation de France
  28. FRM
  29. European Commission (ArtForce)
  30. European Research Council (ERC)
  31. LabEx Immuno-Oncology
  32. SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
  33. SIRIC Cancer Research and Personalized Medicine (CARPEM)
  34. Paris Alliance of Cancer Research Institutes (PACRI)

Ask authors/readers for more resources

Several insults cause the inner mitochondrial membrane to abruptly lose osmotic homeostasis, hence initiating a regulated variant of cell death known as `mitochondria' permeability transition' (MPT)-driven necrosis. MPT provides an etiological contribution to several human disorders characterized by the acute loss of post-mitotic cells, including cardiac and cerebral ischemia. Nevertheless, the precise molecular determinants of MPT remain elusive, which considerably hampers the development of clinically implementable cardio- or neuroprotective strategies targeting this process. We summarize recent findings shedding new light on the supramolecular entity that mediates MPT, the so-called 'permeability transition pore complex' (PTPC). Moreover, we discuss hitherto unresolved controversies on MPT and analyze the major obstacles that still preclude the complete understanding and therapeutic targeting of this process.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available